Best Practices in Chronic Myeloid Leukemia Monitoring and Management. (31st March 2016)

• Record Type: Journal Article
• Authors: Soverini, Simona; De Benedittis, Caterina; Mancini, Manuela; Martinelli, Giovanni
• Is Part Of: Oncologist. Volume 21:Number 5(2016)
• Page Start: 626
• Page End: 633
• Publication Date: 2016-03-31
• Subjects: Leukemia, chronic myeloid -- BCR-ABL1 -- Tyrosine kinase inhibitor -- Minimal residual disease -- Molecular testing; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2015-0337
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract: Optimal use of current therapeutic opportunities for chronic myeloid leukemia patients requires integration of clinical and laboratory monitoring. Assessment of molecular response (MR) by real-time quantitative polymerase chain reaction is the most sensitive way to monitor tyrosine kinase inhibitor (TKI) treatment efficacy. Besides major molecular response, which has emerged as a safe haven for survival since the initial studies of first-line imatinib treatment, two additional MR milestones have recently been defined: early molecular response and deep molecular response. The achievement of such MR milestones within defined time points during therapy is thought to draw the ideal trajectory toward optimal long-term outcome and, possibly, successful treatment discontinuation. Sensitive and reproducible MR measurement and proper interpretation of MR results are therefore critical to correctly inform therapeutic decisions. In patients who do not achieve an optimal response to TKI therapy, BCR-ABL1 mutation screening should also be performed, because it may deliver useful information for TKI choice. This review aims to help clinicians apply and translate the latest response definitions and clinical recommendations into practice. We provide a critical update on how these recommendations have incorporated MR levels in the clinical decision algorithms and how detection of BCR-ABL1 mutations should be interpreted. We also include a practical guide for pathologists and molecular biologists to best perform molecular testing and for hematologists and oncologists to best integrate it into routine practice. Abstract : To correctly inform therapeutic decisions, this review gives a critical update on how molecular response levels are incorporated in clinical decision algorithms and how detection of BCR-ABL1 mutations should be interpreted. The review provides a practical guide for molecular testing and the interpretation and contextualization of the results.